Tiny clinical trials comparing them head-to-head at the different stages of prostate cancer might be wanted. This may be done with asymptomatic men who may have early advanced-phase prostate cancer (e.g. PSA > 60 ng/ml); a downward modify of PSA might be very easily utilised being a appropriate biomarker endpoint in reasonably smaller and quick-phr